Evidence map›Paper›PMID 32142111›Full record

ArticleJAMA internal medicine2020

Severe Lung Injury Associated With Use of e-Cigarette, or Vaping, Products-California, 2019.

Amy Heinzerling, Christina Armatas, Ellora Karmarkar, Kathleen Attfield, Weihong Guo, Yun Wang, Gordon Vrdoljak, Bahman Moezzi, Dadong Xu, Jeff Wagner and 4 more

Open access · bronzeAbstract readMulticenter Study
In one paragraph

Article in JAMA internal medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 2 pooled it
4.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 2 syntheses or guidelines pooled it, 46 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Comparing Cannabis Use for Pain to Use for Other Reasons in Primary Care Patients.Journal of the American Board of Family Medicine : JABFM · 2024
    Article
  9. E-cigarette use-associated lung injury (EVALI).Pneumologie (Stuttgart, Germany) · 2024
    Article
  10. Article
  11. THC and CBD: Villain versus Hero? Insights into Adolescent Exposure.International journal of molecular sciences · 2023
    Review
  12. Article
  13. Article
  14. Review
  15. Vaping-associated lung illness (VALI) in Canada: a descriptive analysis of VALI cases reported from September 2019 to December 2020.Health promotion and chronic disease prevention in Canada : research, policy and practice · 2022
    Article
  16. Article
  17. Article
  18. Is COVID-19 masking the ongoing youth vaping crisis?Expert review of respiratory medicine · 2021
    Article
  19. Availability and Promotion of Cannabidiol (CBD) Products in Online Vape Shops.International journal of environmental research and public health · 2021
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 1 country.

Amy HeinzerlingCenter for Healthy Communities, California Department of Public Health, Richmond.
Christina ArmatasCenter for Healthy Communities, California Department of Public Health, Richmond.
Ellora KarmarkarEpidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia.
Kathleen AttfieldCenter for Healthy Communities, California Department of Public Health, Richmond.
Weihong GuoCenter for Environmental Health, California Department of Public Health, Richmond.
Yun WangCenter for Environmental Health, California Department of Public Health, Richmond.
Gordon VrdoljakCenter for Environmental Health, California Department of Public Health, Richmond.
Bahman MoezziCenter for Environmental Health, California Department of Public Health, Richmond.
Dadong XuCenter for Environmental Health, California Department of Public Health, Richmond.
Jeff WagnerCenter for Healthy Communities, California Department of Public Health, Richmond.
Jefferson FowlesCenter for Healthy Communities, California Department of Public Health, Richmond.
Charity DeanOffice of the Director, California Department of Public Health, Sacramento.
Kristin J CummingsCenter for Healthy Communities, California Department of Public Health, Richmond.
Jason A WilkenCenter for Healthy Communities, California Department of Public Health, Richmond.
California Department of Public Health · USCenter for Environmental Health · USCenters for Disease Control and Prevention · USEpidemic Intelligence Service · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Importance: Since August 2019, more than 2700 patients have been hospitalized with e-cigarette, or vaping, product use-associated lung injury (EVALI) across the United States. This report describes the outbreak in California, a state with one of the highest case counts and with a legal adult-use (recreational) cannabis market. Objective: To present clinical characteristics and vaping product exposures of patients with EVALI in California. Design, Setting, and Participants: Case series describing epidemiologic and laboratory data from 160 hospitalized patients with EVALI reported to the California Department of Public Health by local health departments, who received reports from treating clinicians, from August 7 through November 8, 2019. Exposures: Standardized patient interviews were conducted to assess vaping products used, frequency of use, and method of product acquisition. Vaping products provided by a subset of patients were tested for active ingredients and other substances. Main Outcomes and Measures: Demographic and clinical characteristics, level of care, and outcomes of hospitalization were obtained from medical record review. Results: Among 160 patients with EVALI, 99 (62%) were male, and the median age was 27 years (range, 14-70 years). Of 156 patients with data available, 71 (46%) were admitted to an intensive care unit, and 46 (29%) required mechanical ventilation. Four in-hospital deaths occurred. Of 86 patients interviewed, 71 (83%) reported vaping tetrahydrocannabinol (THC)-containing products, 36 (43%) cannabidiol (CBD)-containing products, and 39 (47%) nicotine-containing products. Sixty-five of 87 (75%) THC-containing products were reported as obtained from informal sources, such as friends, acquaintances, or unlicensed retailers. Of 87 vaping products tested from 24 patients, 49 (56%) contained THC. Vitamin E or vitamin E acetate was found in 41 (84%) of the THC-containing products and no nicotine products. Conclusions and Relevance: Patients' clinical outcomes and vaping behaviors, including predominant use of THC-containing products from informal sources, are similar to those reported by other states, despite California's legal recreational cannabis market. While most THC products tested contained vitamin E or vitamin E acetate, other underlying cause(s) of injury remain possible. The California Department of Public Health recommends that individuals refrain from using any vaping or e-cigarette products, particularly THC-containing products from informal sources, while this investigation is ongoing.

Indexed as

Electronic Nicotine Delivery SystemsPublic HealthAdolescentAdultAgedCaliforniaFemaleHospitalizationHumansIncidenceLung InjuryMaleMiddle AgedRetrospective StudiesSurvival RateVaping

Identifiers

PMID32142111
PMCPMC7060503
OpenAlexW3010130601

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.